Multimodal treatment and management strategies for intracranial hemangiopericytoma
| Autor: | Xinguang Yu, Bainan Xu, Dingbiao Zhou, Yang Yang, Lifeng Chen, Qiu-ping Gui |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Diagnostic Imaging Male medicine.medical_specialty Adolescent medicine.medical_treatment Tumor resection Radiosurgery Metastasis Young Adult Physiology (medical) medicine Humans Multimodal treatment Radical surgery Retrospective Studies Hemangiopericytoma Brain Neoplasms business.industry General Medicine Middle Aged medicine.disease Combined Modality Therapy Surgery Survival Rate Radiation therapy Treatment Outcome Neurology Serial imaging Female Radiotherapy Adjuvant Neurology (clinical) Neoplasm Recurrence Local business |
| Zdroj: | Journal of Clinical Neuroscience. 22:718-725 |
| ISSN: | 0967-5868 |
| Popis: | Intracranial hemangiopericytoma (HPC) is a rare malignant meningothelial tumor. The authors retrospectively reviewed the long-term clinical outcomes of patients with HPC with regard to treatment modalities and histopathological grades. Eighteen women and 20 men (mean age 38.5 years, range, 18-62 years) were observed over an average follow-up period of 61 months (range, 15-133 months) between 2003 and 2013. The initial treatment modalities included total tumor resection followed by conventional radiotherapy (RT) (n=27), and subtotal tumor resection followed by stereotactic radiosurgery (n=11). One patient (3%) had permanent neurological deficits, and six patients (16%) died. Thirteen patients (34%) suffered recurrence. One year, 5 year, and 10 year recurrence-free survival rates were 100%, 70%, and 39%, respectively. Five patients (13%) developed metastasis. One year, 5 year, and 10 year metastasis-free survival rates were 100%, 89%, 74%, respectively. Low grade tumors were associated with longer overall survival, recurrence-free interval and metastasis-free interval (log-rank, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect